(AMED) Amedisys - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US0234361089
AMED: Home Care, Hospice Care, Rehabilitation Services, Nursing Services
Amedisys Inc. (NASDAQ:AMED) stands as a notable player in the healthcare services sector, operating through three distinct segments: Home Health, Hospice, and High Acuity Care. This structure positions the company to address diverse patient needs, from recovery and palliative care to complex medical conditions managed in home settings.
The Home Health segment is pivotal, offering skilled nursing, rehabilitation therapies, and social services to prevent hospital readmissions. This is increasingly relevant as healthcare shifts towards cost-effective, home-based care, driven by an aging population and the need for chronic disease management.
The Hospice segment provides end-of-life care, focusing on comfort and support for terminally ill patients. This service is both compassionate and cost-effective, addressing a growing demographic need as the population ages.
High Acuity Care is a niche offering, delivering intensive care typically found in hospitals or skilled nursing facilities, directly to patients homes. This segment highlights Amedisys commitment to innovative care delivery, aligning with trends towards home-based healthcare solutions.
Financially, Amedisys boasts a market cap of around $3 billion, reflecting its established presence. The trailing P/E of 36.56 indicates a premium valuation, likely due to growth expectations. The forward P/E of 18.73 suggests anticipated earnings growth. A P/B ratio of 2.64 and P/S of 1.31 underscore investor confidence in future prospects, though they also signal a need for scrutiny regarding valuation justifyability.
In conclusion, Amedisys is strategically positioned in a growing industry, with a diversified service offering. Investors should consider both the promising market trends and the current valuation metrics when evaluating this opportunity.
Additional Sources for AMED Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
AMED Stock Overview
Market Cap in USD | 3,022m |
Sector | Healthcare |
Industry | Medical Care Facilities |
GiC Sub-Industry | Health Care Services |
IPO / Inception | 1994-08-17 |
AMED Stock Ratings
Growth 5y | -44.5% |
Fundamental | 19.8% |
Dividend | 0.0% |
Rel. Strength Industry | -1.1 |
Analysts | 2.9/5 |
Fair Price Momentum | 86.45 USD |
Fair Price DCF | 151.21 USD |
AMED Dividends
No Dividends PaidAMED Growth Ratios
Growth Correlation 3m | 59.7% |
Growth Correlation 12m | -23.1% |
Growth Correlation 5y | -80% |
CAGR 5y | -7.56% |
CAGR/Max DD 5y | -0.10 |
Sharpe Ratio 12m | -0.11 |
Alpha | -6.71 |
Beta | 0.35 |
Volatility | 8.15% |
Current Volume | 280.7k |
Average Volume 20d | 288.6k |
As of March 15, 2025, the stock is trading at USD 92.57 with a total of 280,668 shares traded.
Over the past week, the price has changed by +0.22%, over one month by -0.03%, over three months by +7.87% and over the past year by -0.23%.
Neither. Based on ValueRay Fundamental Analyses, Amedisys is currently (March 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 19.76 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of AMED as of March 2025 is 86.45. This means that AMED is currently overvalued and has a potential downside of -6.61%.
Amedisys has received a consensus analysts rating of 2.90. Therefor, it is recommend to hold AMED.
- Strong Buy: 0
- Buy: 1
- Hold: 8
- Sell: 0
- Strong Sell: 1
According to ValueRays Forecast Model, AMED Amedisys will be worth about 93.7 in March 2026. The stock is currently trading at 92.57. This means that the stock has a potential upside of +1.17%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 97.4 | 5.2% |
Analysts Target Price | 96.9 | 4.6% |
ValueRay Target Price | 93.7 | 1.2% |